Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If You Use a Screen Reader

This content is available through Read Online (Free) program, which relies on page scans. Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.

Combination Brain and Systemic Injections of AAV Provide Maximal Functional and Survival Benefits in the Niemann-Pick Mouse

Marco A. Passini, Jie Bu, Jonathan A. Fidler, Robin J. Ziegler, Joseph W. Foley, James C. Dodge, Wendy W. Yang, Jennifer Clarke, Tatyana V. Taksir, Denise A. Griffiths, Michael A. Zhao, Catherine R. O'Riordan, Edward H. Schuchman, Lamya S. Shihabuddin and Seng H. Cheng
Proceedings of the National Academy of Sciences of the United States of America
Vol. 104, No. 22 (May 29, 2007), pp. 9505-9510
Stable URL: http://www.jstor.org/stable/25427883
Page Count: 6
  • Read Online (Free)
  • Subscribe ($19.50)
  • Cite this Item
Since scans are not currently available to screen readers, please contact JSTOR User Support for access. We'll provide a PDF copy for your screen reader.
Combination Brain and Systemic Injections of AAV Provide Maximal Functional and Survival Benefits in the Niemann-Pick Mouse
Preview not available

Abstract

Niemann-Pick disease (NPD) is caused by the loss of acid sphingomyelinase (ASM) activity, which results in widespread accumulation of undegraded lipids in cells of the viscera and CNS. In this study, we tested the effect of combination brain and systemic injections of recombinant adeno-associated viral vectors encoding human ASM (hASM) in a mouse model of NPD. Animals treated by combination therapy exhibited high levels of hASM in the viscera and brain, which resulted in near-complete correction of storage throughout the body. This global reversal of pathology translated to normal weight gain and superior recovery of motor and cognitive functions compared to animals treated by either brain or systemic injection alone. Furthermore, animals in the combination group did not generate antibodies to hASM, demonstrating the first application of systemic-mediated tolerization to improve the efficacy of brain injections. All of the animals treated by combination therapy survived in good health to an investigator-selected 54 weeks, whereas the median lifespans of the systemic-alone, brain-alone, or untreated ASM knockout groups were 47, 48, and 34 weeks, respectively. These data demonstrate that combination therapy is a promising therapeutic modality for treating NPD and suggest a potential strategy for treating disease indications that cause both visceral and CNS pathologies.

Page Thumbnails

  • Thumbnail: Page 
9505
    9505
  • Thumbnail: Page 
9506
    9506
  • Thumbnail: Page 
9507
    9507
  • Thumbnail: Page 
9508
    9508
  • Thumbnail: Page 
9509
    9509
  • Thumbnail: Page 
9510
    9510